What we expect from anticoagulant therapy in 2014

Abstract

n addition to traditional antikogulancií low molecular weight heparin and warfarin are used more and more new oral anticoagulants (NOAC) - direct factor Xa inhibitor apixaban and rivaroxaban a direct thrombin inhibitor dabigratran.

Keywords

• apixaban
• rivaroxaban
• edoxaban
• dabigatran
• warfarin
• individual risk